Glucotrack, Inc. (GCTK): Nasdaq/NYSE listing notice — GlucoTrack receives Nasdaq delisting notice for equity deficiency

Glucotrack, Inc.

Stockholders' equity was $2,355,000 as of Sept 30, 2022, below Nasdaq's $2,500,000 minimum.
Company has 45 days (until Jan 6, 2023) to submit a compliance plan to Nasdaq.
Failure to regain compliance may lead to delisting of common stock.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Glucotrack, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 22, 2022, Nasdaq provided notice that pursuant to Nasdaq Listing Rule 5550(b)(1), GlucoTrack, Inc. (the “Company”) is required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Since its 10-Q for the period ended September 30, 2022 reported stockholders’ equity of $2,355,000, and as of November 22, 2022, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complies with the Rule. The Company has a 45-day period ending on January 6, 2023 to submit a plan of compli

View on SEC.gov

Browse all listing & compliance notices →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-033750

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.